Prostate cancer risk

Prostate cancer risk is a clinical and epidemiological construct representing the statistical probability of an individual developing prostate malignancy [9]. It is not a specific therapeutic target, such as a protein, receptor, or enzyme; rather, it is a complex phenotype influenced by a combination of advancing age, ethnicity, family history, and genetic factors [4, 14]. Molecularly, this risk is often associated with germline mutations in DNA repair genes like BRCA2 and BRCA1, or transcription factors such as HOXB13 [5, 10]. While drugs target biological pathways like the androgen receptor (AR) signaling axis or PARP in established disease, 'prostate cancer risk' itself serves as a parameter for screening and preventive health strategies rather than a direct site for pharmacological intervention [2, 6, 11]. Genetic markers like polygenic risk scores and PSA levels are used as biomarkers to assess this susceptibility [3, 13]. Consequently, this entry refers to a disease susceptibility state or clinical risk profile rather than a druggable biological entity [1, 12].

Other names

Prostate cancer susceptibilityGenetic risk of prostate cancerHereditary prostate cancer riskPCa risk

Not applicable